What is the health economic evidence profile for NP guided therapy versus usual care?
The health economic evidence profile for NP guided therapy versus usual care is summarized in Table 83. This includes two health economic evaluations that were identified with the relevant comparison and have been included in this review. The health economic evidence profile includes costs, effects, incremental costs, incremental effects, cost-effectiveness, and uncertainty. The study by Larame directly applies to the comparison and has minor limitations. It includes a cost-utility analysis with Monte Carlo simulation model and has a lifetime horizon modelled. The population is split into multiple sub-groups, including patients with CHF and LVSD, and patients with CHF and LVSD aged less than 75 years and 75 years or older. The incremental cost for this comparison was found to be NR, while the incremental effects were found to be NR. The baseline probability cost- effectiveness ratio was found to be 2,871 per QALY gained. 